Skip to content

Ayurvedic treatment of katigrah(Lumbar Spondylosis).

Randomized Controlled Trial on Rasnasaptaka Ghanavati with Ashwagandhadi-Kshirbasti on Katigrah with Special Reference to Lumbar Spondylosis.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019952
Enrollment
70
Registered
2019-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M45-M49- Spondylopathies

Interventions

Intervention1: Ashwagandhadi Kshirbasti with Rasnasaptaka Ghanvati: Ashwagandhadi Kshirbasti 240ml OD with Rasnasaptaka Ghanvati 500mg BD at Apankala for 15 days then Rasnasaptaka Ghanvati 500mg B

Sponsors

Self Swapnalee Shanklar More PG Kayachikitsa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The Roland and Morris low back pain and disability questionnaire; if RDQ score > 5 2. Radiological degenerative changes in Lumbar spine. 3. Patients having sign and symptoms of Katigrah according to classics. 4. Patient willing and able to participate in the study. 5. Chronic low back pain more than three months. 6. Patients of either sex aged between 18- 70 years irrespective of caste, religion, socio economic & educational status.

Exclusion criteria

Exclusion criteria: 1. History of any fracture of vertebral joint/ surgical/ diagnostic intervention with reference to affected joints will be excluded. 2. Gross disability in performing daily normal routine i.e. bedridden patient or confined to a wheelchair will be excluded. 3. Patient with co-morbidities such as gouty arthritis, rheumatoid arthritis or psoriatic arthritis and tubercular arthritis. 4. Patient with any deformity of hip or back altering the gait and posture of the patient, ankylosing spondylitis, pelvic inflammatory disorders. 5. Patient with uncontrolled hypertension (>=160/100mm of Hg) and uncontrolled diabetes (Blood sugar level fasting >125mg/dl and post lunch >200mg/dl) will be ruled out. 6. Patient with evidence of malignancy. 7. Patient on prolonged (>=6weeks) medication with corticosteroids, non-steroidal antiinflammatory drug, antidepressants, anti-cholinergic etc. or any drugs that may influence on the outcome of the study. 8. Patient who have a past history of any other systemic disorders will be excluded in doubtful cases. 9. Pregnant / lactating women. 10. Patients who had participated in any other clinical trial since last six months. 11. Those patients contraindicated for Basti will be excluded from study.

Design outcomes

Primary

MeasureTime frame
Rasnasaptaka Ghanavati and Ashwagandhadi-Kshirbasti will be as effective as Erandmula Ghanvati and Panchatikta-Kshirbasti in the management of Katigrah with special reference to Lumbar SpondylosisTimepoint: 30 Days

Secondary

MeasureTime frame
To review and study the literature of Katigrah and Lumbar SpondylosisTimepoint: 30 Days

Countries

India

Contacts

Public ContactDr Ashish Thatere

Government Ayurved College and hospital Nagpur

ashish.thatere@gmail.com9423406821

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026